3rd Annual RAS Targeted Drug Development Summit!
Evvnt Promotion / evvnt
Archivo
21.09.2021 - 23.09.2021 Online
Time: 8:00 am - 5:15 pm
Temas de la conferencia
As promising clinical trial data emerges for KRAS G12C inhibitors and with strong chances of receiving FDA approval this year, the once undruggable RAS family of proteins no longer seem impossible to be cracked. This has undoubtedly resulted in great momentum in the field of oncology to develop RAS targeted therapies that safely, effectively and selectively drug all RAS driven cancers beyond those caused by G12C mutation.
As promising clinical trial data emerges for KRAS G12C inhibitors and with strong chances of receiving FDA approval this year, the once undruggable RAS family of proteins no longer seem impossible to be cracked. This has undoubtedly resulted in great momentum in the field of oncology to develop RAS targeted therapies that safely, effectively and selectively drug all RAS driven cancers beyond those caused by G12C mutation.
Organizador profesional (PCO)
Hanson Wade
Hanson Wade
Observaciones
Brochure: https://go.evvnt.com/790905-3?pid=4832
Speakers: Gregory Friberg, Vice President Global Development and Oncology Therapeutic Area Head, Amgen, Susan Yang, Adagrasib Medical Lead, Mirati Therapeutics and more
Brochure: https://go.evvnt.com/790905-3?pid=4832
Speakers: Gregory Friberg, Vice President Global Development and Oncology Therapeutic Area Head, Amgen, Susan Yang, Adagrasib Medical Lead, Mirati Therapeutics and more
Información e inscripción:
https://go.evvnt.com/790905-0?pid=4832
Mr. Customer Service
Medicina General
Idioma
Inglés
Inglés
Cuota del Congreso
USD 2099.00 - USD 4198.00
USD 2099.00 - USD 4198.00
Los participantes esperaban
1000
1000
Cantacto organizador
83 Great Titchfield Street
W1W 6RH London
United Kingdom
83 Great Titchfield Street
W1W 6RH London
United Kingdom
"Going International fomenta el acceso a la educación y a la formación continua independientemente de fronteras sociales, geográficas y nacionales."
